The regulatory finish line is in sight for a growing number of cancer vaccines that represent diverse mechanisms, manufacturing platforms and components, all designed to harness the patient’s own immune system to fight cancer with a high degree of efficacy and few side effects. A number of those companies will be presenting clinical data on their projects at the coming American Society of Clinical Oncology meeting in Chicago June 1-5.
Along with news on the firm’s second-generation projects, four abstracts will be presented further elucidating the character of Dendreon Corp.’s breakthrough prostate cancer therapy Provenge (sipuleucel-T), the first approved...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?